Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filorexant Augmentation in MDD
NCT01554176Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- May 2012
- Primary completion
- Sep 2013
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of filorexant in major depressive disorder (MDD), sponsored by Merck & Co.. Started May 2012; status: terminated.
02
Drugs
filorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01554176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01554176.